COMMUNIQUÉS West-GlobeNewswire

Teladoc Health Reports Fourth Quarter and Full Year 2023 Results
20/02/2024
Fourth quarter 2023 revenue increase of 4% and full year 2023 revenue increase of 8% to $2,602.4 million Fourth quarter 2023 net loss of $28.9 million , or $0.17 per share, and full year 2023 net loss of $220.4 million [...]
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
20/02/2024
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today [...]
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
20/02/2024
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
20/02/2024
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Caira Surgical to Showcase Radar Surgical Tracking Technology at LSI USA '24 Emerging Medtech Summit
20/02/2024
NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Caira Surgical, the pioneer in Radar Surgical Tracking for robotic and navigated joint replacement surgery, today announced its upcoming participation in the prestigious LSI [...]
CorVel Earns 2024 Great Place To Work Certification™
20/02/2024
FORT WORTH, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ:CRVL), is proud to be Certified™ by Great Place To Work ® for the 4th year in a row. The prestigious award is based entirely on what current [...]
New report exposes harmful impact of Ford government’s privatization scheme on local public hospitals: Health Coalition
20/02/2024
Attn: Assignment Editor TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- As the Ford government counters horror stories about unprecedented emergency department wait times, burgeoning deficits, and an unrelenting staffing [...]
IBA – Transparency Notification
20/02/2024
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February 20, 2024 06:00 Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
IBA - PUBLICATION RELATIVE À UNE NOTIFICATION DE TRANSPARENCE
20/02/2024
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 20 février 2024, 18 :00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
Cepham Introduces Senolytics Inspired by Ayurveda and TCM for Sustainable Aging
20/02/2024
SOMERSET, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cepham , a leader in Ayurvedic nutraceuticals research and sustainable self-care solutions, has announced the expansion of its Sustainable Aging product line to include [...]
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
20/02/2024
SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A [...]
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024
20/02/2024
BOSTON and ROLLE, Switzerland, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial [...]
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
20/02/2024
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial – [...]
LiveCare Inc. (OTCMKTS: LVCE) Announces Stellar Revenue Growth, Strategic Patient Expansion in Telehealth for Diabetes Care, and Aspirations for NASDAQ Listing
20/02/2024
Venice, FL, USA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- LiveCare Inc. (OTCMKTS: LVCE), a leading telehealth company specializing in health coaching and comprehensive services for individuals with diabetes, is thrilled to [...]
BioSig Announces Reduction of its Workforce
20/02/2024
Westport, CT, Feb. 20, 2024 (GLOBE NEWSWIRE) -- -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company, today announced that it has terminated a significant number of its [...]
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries
20/02/2024
Incidence of pressure injuries reduced by 50% during the study period As a decision support device, PressureSafe, can support early detection of pressure injuries, potentially setting a new standard of care to address a [...]
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
20/02/2024
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
20/02/2024
ST. LOUIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
20/02/2024
Repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection, and a pharmacodynamic profile greater than injection Company believes completion of repeat [...]

Pages